Y-Biologics, Inc. (KOSDAQ:338840)
South Korea · Delayed Price · Currency is KRW 13,550
+450 (3.44%)
At close: Jun 11, 2026
Y-Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | 2,913 | 5,763 | 3,479 | 4,151 | 4,847 |
Other Revenue | - | - | - | - | -0 | - |
| 2,788 | 2,913 | 5,763 | 3,479 | 4,151 | 4,847 | |
Revenue Growth (YoY) | -44.55% | -49.45% | 65.64% | -16.18% | -14.37% | -27.99% |
Cost of Revenue | 598.58 | 618.98 | 1,495 | 1,141 | 2,895 | 2,528 |
Gross Profit | 2,189 | 2,294 | 4,267 | 2,338 | 1,255 | 2,319 |
Selling, General & Admin | 4,015 | 3,999 | 4,704 | 4,974 | 5,130 | 5,143 |
Research & Development | 8,251 | 6,783 | 6,828 | 6,650 | 11,941 | 12,589 |
Amortization of Goodwill & Intangibles | 130.81 | 122.27 | 123.04 | 119.24 | 117.1 | 97.17 |
Other Operating Expenses | 116.52 | 120.16 | 188.11 | 147.22 | 226.04 | 106.36 |
Operating Expenses | 13,080 | 11,563 | 12,714 | 12,481 | 20,086 | 19,684 |
Operating Income | -10,891 | -9,269 | -8,447 | -10,143 | -18,830 | -17,365 |
Interest Expense | -2,105 | -1,259 | -42.93 | -143.76 | -103.44 | -114.73 |
Interest & Investment Income | 756.02 | 546.53 | 496.33 | 68.72 | 66.8 | 115.42 |
Currency Exchange Gain (Loss) | 155.54 | 2.42 | 38.46 | -55.89 | 96.53 | 309.83 |
Other Non Operating Income (Expenses) | -32,323 | -31,992 | 1,513 | -10,922 | 138.54 | -32.11 |
EBT Excluding Unusual Items | -44,407 | -41,971 | -6,442 | -21,196 | -18,632 | -17,086 |
Gain (Loss) on Sale of Investments | -20.7 | -20.7 | - | - | - | - |
Gain (Loss) on Sale of Assets | -32.55 | -32.55 | -0 | 324.62 | -172.61 | 15.23 |
Pretax Income | -44,461 | -42,025 | -6,442 | -20,871 | -18,804 | -17,071 |
Net Income | -44,461 | -42,025 | -6,442 | -20,871 | -18,804 | -17,071 |
Net Income to Common | -44,461 | -42,025 | -6,442 | -20,871 | -18,804 | -17,071 |
Shares Outstanding (Basic) | 15 | 15 | 15 | 13 | 12 | 12 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 13 | 12 | 12 |
Shares Change (YoY) | 1.37% | 0.80% | 18.01% | 1.87% | 1.01% | 21.93% |
EPS (Basic) | -2966.08 | -2821.86 | -436.00 | -1667.00 | -1530.00 | -1403.00 |
EPS (Diluted) | -2966.08 | -2821.86 | -436.00 | -1667.00 | -1530.00 | -1403.00 |
Free Cash Flow | -8,038 | -6,865 | -7,003 | -7,801 | -11,193 | -16,720 |
Free Cash Flow Per Share | -536.23 | -460.95 | -473.97 | -623.04 | -910.72 | -1374.20 |
Gross Margin | 78.53% | 78.75% | 74.05% | 67.21% | 30.25% | 47.85% |
Operating Margin | -390.67% | -318.20% | -146.58% | -291.53% | -453.68% | -358.23% |
Profit Margin | -1594.90% | -1442.67% | -111.78% | -599.90% | -453.06% | -352.17% |
Free Cash Flow Margin | -288.34% | -235.66% | -121.52% | -224.21% | -269.68% | -344.94% |
EBITDA | -8,918 | -7,337 | -6,409 | -7,788 | -15,869 | -15,049 |
EBITDA Margin | - | -251.87% | -111.21% | -223.86% | - | - |
D&A For EBITDA | 1,973 | 1,932 | 2,038 | 2,354 | 2,962 | 2,316 |
EBIT | -10,891 | -9,269 | -8,447 | -10,143 | -18,830 | -17,365 |
EBIT Margin | - | - | -146.58% | -291.53% | - | - |
Advertising Expenses | - | 57.54 | 71.25 | 55.98 | 51.34 | 101.71 |